TY - JOUR
T1 - Valproate competes with palmitate for binding to serum albumin
AU - Vorum, Henrik
AU - Andersen, Signe
AU - Brodersen, Rolf
PY - 1989
Y1 - 1989
N2 - Addition of sodium valproate (VPA) to a buffered solution of human serum albumin (HSA) or to serum reduces binding affinity for palmitate. A maximal pharmacologic VPA concentration, 700 microM, added to a 300-microM albumin solution, reduces the reserve albumin concentration for binding of palmitate by a factor of 0.64. One possible site model explaining these findings may be that VPA competes strongly with one among three palmitate molecules, bound to albumin with high affinity, and induces a weaker displacement of a second palmitate.
AB - Addition of sodium valproate (VPA) to a buffered solution of human serum albumin (HSA) or to serum reduces binding affinity for palmitate. A maximal pharmacologic VPA concentration, 700 microM, added to a 300-microM albumin solution, reduces the reserve albumin concentration for binding of palmitate by a factor of 0.64. One possible site model explaining these findings may be that VPA competes strongly with one among three palmitate molecules, bound to albumin with high affinity, and induces a weaker displacement of a second palmitate.
KW - Binding, Competitive
KW - Humans
KW - Osmolar Concentration
KW - Palmitates/metabolism
KW - Palmitic Acids/metabolism
KW - Serum Albumin/metabolism
KW - Valproic Acid/metabolism
U2 - 10.1111/j.1528-1157.1989.tb05311.x
DO - 10.1111/j.1528-1157.1989.tb05311.x
M3 - Journal article
C2 - 2498075
SN - 0013-9580
VL - 30
SP - 370
EP - 973
JO - Epilepsia
JF - Epilepsia
IS - 3
ER -